Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial
暂无分享,去创建一个
A. Schwarer | D. White | T. Hughes | S. Branford | A. Grigg | C. Slader | D. Yeung | M. Hertzberg | C. Arthur | D. Ross | C. Forsyth | D. Hiwase | M. Osborn | Y. Kwan | R. Filshie | S. Issa | A. Mills | M. Kornhauser | T. Hughes